Skip to main content

Table 1 Patient demographics for the safety population

From: Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement

  MRA
  2 mg/kg (n = 6) 4 mg/kg (n = 6) 8 mg/kg (n = 6)
Age (years)    
   Mean ± SD 6.3 ± 3.33 7.7 ± 5.13 4.8 ± 1.83
   Median 6.5 6.5 5.0
   Range 3, 10 3, 17 2, 7
Gender    
   Male (n) 3 6 1
   Female (n) 3 0 5
Race    
   Caucasian (n) 6 6 6
Weight (kg)    
   Mean ± SD 23.47 ± 10.954 27.45 ± 14.479 19.63 ± 4.286
   Median 17.95 24.05 19.90
   Range 13.8, 38.0 16.2, 55.5 14.6, 23.6
Height (cm)    
   Mean ± SD 108.3 ± 14.07 117.5 ± 23.84 108 ± 12.92
   Median 105.5 111.5 102.0
   Range 90, 126 95, 159 94, 127
  1. SD, standard deviation.